PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models... PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.
- Mechanism
- Curator reviewed
PX-478 is a novel small molecule compound that inhibits the activity of hypoxia inducible factor (HIF)-1 alpha, a transcription factor that controls the expression of a number of genes important for growth and survival of cancer cells. Genes regulated by HIF-1 alpha contribute to diverse functions including new blood vessel growth (angiogenesis), use of glucose for energy, and protection against apoptosis (programmed cell death). Preclinical data have demonstrated that PX-478 can induce apoptosis in experimental tumor models, as well as the down-regulation of factors which control angiogenesis, such as vascular endothelial growth factor (VEGF).
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
- Formula / weight
- C13H20Cl4N2O3 · 394.11 g/mol (avg)
- Code names
- PX-478
Resolves to
GIGCDIVNDFQKRA-LTCKWSDVSA-NSMILESCl.Cl.N[C@@H](CC1=CC=C(C=C1)[N+]([O-])(CCCl)CCCl)C(O)=OWhat you can answer from here — as of April 02, 2025
Which drugs share a target with PX-478, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account